BE
BETRF.US BetterLife Pharma Inc
- Market cap
- USD 91.8M
- P/E
- -
- P/B
- 13.65x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jul 2026.
Is BETRF.US undervalued?
Graham numberThe Graham number of BetterLife Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BetterLife Pharma Inc fundamental analysis
No fundamental analysis for BetterLife Pharma Inc yet.
BetterLife Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalati…
Full company profileBetterLife Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BetterLife Pharma Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.64M | -1.16M | -6.46M | -9.20M | -7.95M | -9.97M | -9.26M | -3.21M | -4.72M | -1.81M | -3.47M |
| EBITDA | - | -84.8K | -7.34M | -17.8M | -36.0M | -11.9M | -9.29M | -2.85M | -3.30M | -1.28M | -5.22M |
| Net Income | -8.23M | -150K | -9.15M | -19.6M | -36.4M | -12.2M | -9.02M | -2.89M | -3.52M | -1.50M | -5.39M |
| EPS | - | -0.02 | -0.94 | -1.14 | -0.71 | -0.14 | -0.10 | -0.02 | -0.03 | -0.01 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 174K | 474K | 8.60M | 8.25M | 1.34M | 1.16M | 74.7K | 325K | 225K | 220K | 2.05M |
| Total Liabilities | 2.11M | 530K | 5.09M | 5.59M | 5.95M | 5.04M | 7.61M | 8.02M | 7.59M | 6.71M | 9.70M |
| Shareholders' Equity | -1.93M | -56.0K | 3.51M | 2.66M | -4.61M | -3.88M | -7.53M | -7.70M | -10.7M | -9.78M | -10.9M |
| Cash & Short-term Investments | 147K | 79.6K | 74.8K | 2.68M | 155K | 174K | 8.31K | 37.4K | 8.18K | 12.6K | 974K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -359K | -562K | -4.71M | -7.88M | -7.16M | -11.2M | -1.50M | -2.47M | -2.02M | -625K | -3.29M |
| Capital Expenditure | 543K | 543K | 543K | 543K | 10.2K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -488K | -5.83M | -8.42M | -7.26M | -11.2M | -1.50M | -2.47M | -2.02M | -625K | -3.29M |
| Ratios | |||||||||||
| ROE | - | - | -260.6% | -737.4% | - | - | - | - | - | - | - |
| ROA | -4,732.6% | -31.6% | -106.4% | -237.4% | -2,720.0% | -1,047.0% | -12,065.5% | -889.6% | -1,564.8% | -680.1% | -263.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
BetterLife Pharma Inc dividends
BetterLife Pharma Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jun 26, 2020.
Who owns BetterLife Pharma Inc
- Insiders 14.33%
- Institutions 8.97%
- Public & others 76.71%
- Shares outstanding 651M
- Free float 474M
BetterLife Pharma Inc company profile
- Company name
- BetterLife Pharma Inc
- Ticker
- BETRF.US
- ISIN
- CA08772P2026
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- January
- Address
- 1275 West 6th Avenue, Vancouver, BC, Canada, V6H 1A6
- Phone
- 604 221 0595
- Website
- abetterlifepharma.com
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
BetterLife Pharma Inc management
7- Dr. Ahmad Doroudian Ph.D.Founder, CEO & Director · born 1960
- Ms. Moira Ong C.A., C.P.A., CFAChief Financial Officer · born 1975
- Dr. Hooshmand Sheshbaradaran Ph.D.Chief Operating Officer · born 1957
- Mr. Douglas L. DrysdaleExecutive Chairman & Member of Scientific Advisory Board · born 1970
- Mr. Scott Rudge Ph.D.Head of CMC
- Dr. Mahan Chehrenama D.O.Chief Medical Officer
- Ms. Sheila LeitzingerHead of Clinical Operations